To fight the drug affordability crisis, Trump must crack down on middlemen
The article discusses the challenges faced by Americans in accessing affordable prescription drugs due to the practices of insurance companies and pharmacy benefit managers (PBMs). It highlights how these middlemen create barriers that delay treatment and inflate costs, particularly affecting patients with chronic conditions. The piece calls for the Trump administration to take stronger action against these practices to improve healthcare access and affordability.
- ▪A recent study found that 70% of commercially insured patients face initial claim rejections for new branded medicines.
- ▪Nearly 60% of U.S. adults worry about being able to pay for their medications.
- ▪Four in ten insured adults with chronic conditions say prior authorization is among their greatest healthcare challenges.
Opening excerpt (first ~120 words) tap to expand
Most adult Americans take at least one prescription drug, and for too many, getting that prescription filled means battling the very system that’s supposed to help them. Insurance denials have become alarmingly routine. A recent study found that 70% of commercially insured patients face initial claim rejections for new branded medicines. And even when patients manage to access treatment, affordability remains a major challenge: nearly 60% of U.S. adults worry about being able to pay for their medications. Recommended Stories Nigeria kidnappings: The world’s selective moral outrage Russia’s growing desperation reflected in Ukraine onslaught Rick Crawford should be Trump’s next director of national intelligence At the center of this crisis are the abusive practices of corporate middlemen.
…
Excerpt limited to ~120 words for fair-use compliance. The full article is at Washington Examiner.
Discussion
0 commentsMore from Washington Examiner
